F.D.A. Approves Juul Vapes After Yearslong Delay
The company was required to prove that the products were 'appropriate for the protection of public health' under agency rules. Juul said in a statement that it met the bar, in part, by showing that its products had helped about two million adults quit smoking cigarettes.
The F.D.A. authorized both the e-cigarette system and menthol- and tobacco-flavored cartridges. Though concerns about the health effects of e-cigarettes are mounting, they are still widely viewed by experts as safer than cigarettes.
'Today's F.D.A. authorization of Juul products marks an important step toward making the cigarette obsolete,' K.C. Crosthwaite, the company's chief executive, said in a statement.
Mr. Crosthwaite said underage use of Juul products was 'down 98 percent since 2019, to one-half of 1 percent of youth.'
At least one lawmaker panned the decision. Senator Dick Durbin, Democrat of Illinois, recounted in a statement Thursday that Juul had 'ignited' an epidemic of vaping among youths and 'lied about the harms of their vapes.'
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Biologic Therapeutics Market to Hit $794.5 Billion by 2029
"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative Vaccines" BOSTON, July 28, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Biologic Therapeutic Drugs: Technologies and Global Markets" is projected to increase from $499.2 billion in 2024 to reach $794.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029. This report provides a comprehensive analysis of the global market for biologic therapeutic drugs, segmented by product type (such as mAbs vaccines, and cell and gene therapies), source (mammalian, microbial, others), application (oncology, autoimmune, and infectious diseases), and region (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). It explores key market trends, challenges, and ESG developments, and examines the emerging technologies shaping the industry. The report also includes a competitive landscape analysis with market share rankings and detailed profiles of leading companies. This report is particularly relevant now due to the growing demand for innovative therapies and the rapid advances in regenerative medicine. Increased investments and intensified research activities are accelerating the development of biologic drugs, while a surge in product approvals is expanding treatment options in many medical fields. These factors are collectively driving significant growth in the biologics market, making timely insights into trends, challenges, and competitive dynamics more critical than ever. The factors driving the market's growth include: Growing Demand for Biologics: Biologics are increasingly favored due to their high efficacy, targeted action, and ability to treat complex diseases like cancer and autoimmune disorders. Patients and healthcare providers are turning to these advanced therapies for better outcomes and fewer side effects. Rising Investments in Biopharmaceuticals: The biopharma sector is seeing a surge in funding from pharmaceutical companies, investors, and governments. These investments support research, clinical trials, and manufacturing infrastructure, accelerating the development and availability of biologic drugs. Product Development Collaborations and Agreements: Collaborations between biotech firms and large pharmaceutical companies are common, enabling shared expertise, reduced costs, and faster product development. Licensing deals and joint ventures also help expand market reach and streamline commercialization. Transition Toward Personalized Medicines: Biologics are central to the shift toward personalized medicine, where treatments are tailored to individual genetic profiles. Advances in genomics and diagnostics enable more precise therapies, reducing trial-and-error in treatment. Aging Population and the Prevalence of Chronic Diseases: An aging global population is leading to a higher incidence of chronic diseases such as diabetes, cancer, and arthritis. Biologics offer effective long-term treatment options for these conditions, making them essential in managing the health needs of older adults. Request a sample copy of the global market for biologic therapeutic drugs report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $456.9 billion Market size forecast $794.5 billion Growth rate CAGR of 9.7% for the forecast period of 2024-2029 Segments covered Type, Source, Application, Region Regions covered North America, Europe, Asia-Pacific, Rest of the World(South America and the Middle East and Africa). Countries covered U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy,China, India, Japan, Australia. Market drivers Growing Demand for Biologics Rising Investments in Biopharmaceuticals Product Development Collaborations andAgreements Transition Toward Personalized Medicines Rising Aging Population and the Growing Prevalenceof Chronic Diseases Interesting facts: The biologic therapeutics market is witnessing higher number of approvals for several new therapies and an increase in biologics approvals yearly. In 2023, the market witnessed approvals for breakthrough therapies such as gene editing therapy Casgevy from CRISPR Therapeutics and Vertex Pharmaceuticals and Leqembi (lecanemab) from Eisai for Alzheimer's disease. Emerging startups Arcus Biosciences Allogene Therapeutics Astria Therapeutics Bean Therapeutics HiFiBiO Therapeutics The report addresses the following questions: 1. What is the projected size and growth rate of the market? The global market for biologic therapeutic drugs was valued at $456.9 billion in 2023 and is expected to grow at a CAGR of 9.7% from 2024 to 2029 to reach $794.5 billion by the end of 2029. 2. What factors are driving the growth of the market? The global market for biologics therapeutic drugs is growing due to the world's rising aging population and the growing prevalence of chronic diseases, increasing numbers of product launches, and high demand for personalized medicine. 3. Which market segments are covered in the report? The global market for biologics therapeutic drugs is segmented based on product type, source, application, and region. 4. Which product type segment will be dominant through 2029? The monoclonal antibodies (mAbs) segment will dominate the market through 2029. 5. Which region has the largest market share? North America holds the largest share of the market. Market leaders include: ABBVIE INC. AMGEN INC. ASTRAZENECA BRISTOL-MYERS SQUIBB CO. ELI LILLY AND CO. F. HOFFMANN-LA ROCHE LTD. GILEAD SCIENCES INC. GSK PLC. JOHNSON & JOHNSON SERVICES INC. MERCK & CO. INC. NOVARTIS AG NOVO NORDISK A/S PFIZER INC. REGENERON PHARMACEUTICALS INC. SANOFI Related reports: Antibody Drugs: Technologies and Global Markets: This report provides reviews the global antibody drug market, focusing on monoclonal antibodies (mAbs) used in treating chronic diseases like cancer and autoimmune disorders. It covers market trends, regional analysis, and key companies. Forecasts extend to 2029, highlighting growth in therapeutic applications and technological advances. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Dow Eyes Record High After EU Deal
Dow Jones (DJIA) is flirting with a record high after President Trump and EU Commission President Ursula von der Leyen unveiled a framework deal slashing threatened 30% tariffs on EU goods to 15% and exempting key exports like aircraft and chip equipment. Warning! GuruFocus has detected 7 Warning Sign with NKE. List of 52-Week Lows List of 3-Year Lows List of 5-Year Lows The EU also pledged $600 B in new U.S. investments and another $750 B into energy projects over three years. The Dow opened Monday less than 0.5% below its all?time peak ahead of a packed week that features the July 2930 FOMC meeting and a wave of corporate earnings. Last year the U.S. ran a $235.6 B goods deficit with its largest trading partner, so easing trade friction and fresh capital inflows could help narrow that gap and underpin market gains. Why it matters: Clearer trade rules and massive investment commitments may boost business confidence and spending. Investors will be watching FOMC minutes on Wednesday and upcoming earnings for signs this rally can sustain. This article first appeared on GuruFocus.
Yahoo
25 minutes ago
- Yahoo
Deion Sanders says Randy Moss called 'every other day' during cancer treatment
Deion Sanders and Randy Moss have a lot in common. They were both star athletes that helped define a generation of NFL talent, multi-time Pro Bowl and All-Pro honorees, members of their respective teams' Rings of Honor and members of both the College and Pro Football Hall of Fame. More recently, they've both added another shared experience to their already impressive résumés: cancer survivors. Sanders, 57, revealed in a Monday press conference with his medical team that he had been diagnosed with – and subsequently had defeated – bladder cancer. As he shared details about his cancer battle, Sanders took the time to thank Moss for his support during the treatment. "Randy Moss called me every other day to make sure I was straight," he said. "Randy Moss prayed for me. He and his wife told me what I needed to be doing. He's gone through some things very similar." DEION SANDERS HEALTH ISSUES: A timeline of Colorado coach's history Sanders was referring to Moss's recent battle with bile duct cancer, which led the former Vikings receiver to announce a leave of absence from ESPN's NFL coverage in early December. Moss announced later that month that he was a cancer survivor and returned to ESPN's "Sunday Night Countdown" for Super Bowl 59 coverage in February. The Athletic recently reported Moss would return to "Sunday Night Countdown" full-time for the 2025 season. "Randy Moss, man. I love him to life. Love him more than ever," Sanders said. "He gave me so much strength and so much guidance. And so much love and respect and appreciation." The Colorado Buffaloes' head football coach had been battling his health issue for months – leading him to miss a recruiting event and former Colorado star Travis Hunter's wedding, among other things – before returning to Boulder on Friday. Monday's press conference with his medical team was the first time Sanders publicly disclosed his diagnosis and ensuing treatment. This article originally appeared on USA TODAY: Deion Sanders reveals how Randy Moss supported him amid cancer scare
